Comparative Pharmacology
Head-to-head clinical analysis: LIBERVANT versus MENRIUM 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBERVANT versus MENRIUM 5 2.
LIBERVANT vs MENRIUM 5-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; enhances inhibitory neurotransmission.
Combination of chlordiazepoxide (benzodiazepine) potentiating GABA-A receptor activity, and clidinium (antimuscarinic) blocking muscarinic acetylcholine receptors.
0.25 mg intravenously over 2 minutes, may repeat once after 15 minutes if inadequate response; maximum total dose 0.5 mg.
1 tablet orally every 6-8 hours as needed for anxiety, up to 4 tablets per day. Each tablet contains chlordiazepoxide 5 mg and clidinium bromide 2.5 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in patients with normal renal function; may be prolonged up to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Chlordiazepoxide: 5-30 hours (increases with age, hepatic impairment); Clidinium: 8-12 hours
Primarily renal excretion of unchanged drug (approximately 85%) and glucuronide conjugates (approximately 10%); biliary/fecal excretion accounts for less than 5%.
Chlordiazepoxide: 90-96% renal as metabolites, <5% unchanged; Clidinium: 70-80% fecal, 10-20% renal as metabolites
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination